Posted on 17/08/2010 in Pharmaceutical Company Product News GlaxoSmithKline has been joined by the Medicines for Malaria Venture (MMV) as a contributor to a major initiative to further research into tropical disease.
The not-for-profit venture has agreed to contribute a selection of patents to the Pool for Open Innovation against Neglected Tropical Diseases, which allows participating organisations to share expertise on conditions such as malaria.
GlaxoSmithKline was the first major pharmaceutical company to suggest a pool for neglected tropical disease in February 2009 and has since been joined by Alnylam Pharmaceuticals and the Massachusetts Institute of Technology in providing intellectual property contributions.
Don Joseph, chief operating officer for the pool's administrator BIO Ventures for Global Health, said the participation of a global product development partnership such as MMV will aid the effectiveness of the scheme.
He said it "opens a new dimension for the Pool for Open Innovation by demonstrating the range of organisations supporting the Pool through open access and application of their intellectual property".
Earlier this year, GlaxoSmithKline was named top of the Access to Medicine Foundation's second Access of Medicines Index, recognising its healthcare initiatives in developing nations. Other news stories from 17/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
